Sridhar Banuru, MD
Cardiovascular Disease · Henderson, KYNPI 1649244781
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. Abbott accounts for 61.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $1,792 and has fallen 79.4% since, to $370 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in KY, where the typical reported total is $2,503.
Across 52 payments — averaging $53.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- E.r. Squibb & Sons, L.L.C.$342
- Amgen$165
- Bayer$128
- Nevro Corp.$101
- Novartis$75
- plus $251 from 12 others
Across 1 payment — averaging $15,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$16K
What the payments were for
- Travel & lodging$1,21744%
- Food & beverage$1,55856%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 17 | $1,726 |
| E.r. Squibb & Sons, L.L.C. | 7 | $342 |
| Amgen | 4 | $165 |
| Bayer | 1 | $128 |
| Nevro Corp. | 1 | $101 |
| Novartis | 4 | $75 |
| Daiichi Sankyo Inc. | 3 | $39 |
| Terumo Medical Corporation | 1 | $38 |
| Lundbeck LLC | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $25 |
| Heartflow, Inc. | 1 | $20 |
| Merck | 1 | $16 |
| Johnson & Johnson | 2 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $14 |
| AstraZeneca | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$1,196
- CAMZYOS$251
- Kerendia$128
- Omnia$101
How this compares
$2,789 in reported general payments places this provider in the 50th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 426 | $463,484 |
| EntrestoSacubitril/Valsartan | 212 | $251,774 |
| XareltoRivaroxaban | 123 | $140,513 |
| Repatha SureclickEvolocumab | 147 | $135,866 |
| FarxigaDapagliflozin Propanediol | 75 | $69,916 |
| VascepaIcosapent Ethyl | 38 | $23,185 |
| Praluent PenAlirocumab | 20 | $17,239 |
| Metoprolol Succinate | 1,204 | $14,938 |
| BrilintaTicagrelor | 18 | $13,523 |
| Ranolazine ErRanolazine | 124 | $10,074 |
| Atorvastatin Calcium | 1,087 | $7,692 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 664 | $7,220 |
| Losartan Potassium | 846 | $6,650 |
| Amlodipine Besylate | 850 | $4,362 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 168 | $4,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $11 | $463,484426 claims |
| NovartisEntresto | $75 | $251,774212 claims |
| Johnson & JohnsonXarelto | $15 | $140,513123 claims |
| AstraZenecaFarxiga, Brilinta | $14 | $83,44093 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Henderson
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- William SkinnerLexington$312K
- Prabodh MehtaElizabethtown$133K
- John HarrisLouisville$129K
- David MoliternoLexington$115K
- Rohan SamsonLouisville$94K
- Srinivasa AppakonduHazard$91K
- Muhammad AkbarBowling Green$84K
- Jeffrey ReichardFlorence$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.